Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 9:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 901 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hepatitis C Virus Infection Clear all
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Hepatitis C Positive Donor Into Hepatitis C Negative Recipients

NCT03702218
View directory record Official record
Conditions
Hepatitis C
Interventions
Direct Acting Antivirals
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 9, 2026, 9:46 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

STOP HCC: Mailed HCV Treatment Outreach Program for HCC Prevention for Elevated LFTs

NCT04395118
View directory record Official record
Conditions
Hepatitis C, Hepatocellular Carcinoma
Interventions
Mailed Outreach
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2020 · Synced Oct 9, 2026, 9:46 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected Subjects

NCT00546715
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Daclatasvir, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 49 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
7
States / cities
Anaheim, California • Orlando, Florida • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2015 · Synced Oct 9, 2026, 9:46 AM EDT
Completed Phase 1 Interventional

TD-6450 MAD Study in HCV Infected Subjects

NCT02116543
View directory record Official record
Conditions
Hepatitis C, HCV
Interventions
TD-6450, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 9, 2026, 9:46 AM EDT
Completed Not applicable Interventional Results available

Nurse Case Management to Improve Hepatitis C Care in HIV Co-infection

NCT02707991
View directory record Official record
Conditions
HIV, Hepatitis C, Chronic
Interventions
Nurse Case Management
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 2, 2019 · Synced Oct 9, 2026, 9:46 AM EDT
Completed Phase 2 Interventional

Safety, Tolerability, and Antiviral Activity of ANA598 Administered in Combination With Pegylated Interferon and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection

NCT00978497
View directory record Official record
Conditions
HCV Infection
Interventions
placebo, ANA598, Peginterferon, Ribavirin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
20
States / cities
Anaheim, California • Los Angeles, California • San Clemente, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2017 · Synced Oct 9, 2026, 9:46 AM EDT
Completed Phase 2 Interventional Results available

Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6

NCT01329978
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Sofosbuvir, RBV, PEG
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
44
States / cities
Montgomery, Alabama • Jonesboro, Arkansas • Anaheim, California + 36 more
Source: ClinicalTrials.gov public record
Updated May 26, 2014 · Synced Oct 9, 2026, 9:46 AM EDT
Terminated No phase listed Observational

Treating Hispanic Patients Diagnosed With Hepatitis C Using Boceprevir

NCT01465516
View directory record Official record
Conditions
Hepatitis C Infection
Interventions
Boceprevir
Drug
Lead sponsor
Arrowhead Regional Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Riverside, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2015 · Synced Oct 9, 2026, 9:46 AM EDT
Completed Phase 1Phase 2 Interventional

Study of Safety, Tolerability, and Anti-Viral Effect of Locteron Compared to PEG-Intron in Patients With Chronic Hepatitis C

NCT00593151
View directory record Official record
Conditions
Hepatitis C
Interventions
Locteron (controlled-release interferon alpha 2b), pegylated IFNa2b
Other · Biological
Lead sponsor
Biolex Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Detroit, Michigan • Dallas, Texas • San Antonio, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 9, 2026, 9:46 AM EDT
Completed Phase 3 Interventional Results available

Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant

NCT02032875
View directory record Official record
Conditions
Hepatitis C
Interventions
Daclatasvir, Sofosbuvir, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
Miami, Florida • Ann Arbor, Michigan • Houston, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Oct 9, 2026, 9:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Development and Pilot Testing of a PHCI for Emergency Department Patients Who Decline Rapid HIV/ HCV Screening

NCT04137094
View directory record Official record
Conditions
Hiv, Hepatitis C
Interventions
Persuasive Health Communication Intervention
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 20, 2021 · Synced Oct 9, 2026, 9:46 AM EDT
Completed Phase 4 Interventional Results available

Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).

NCT00087607
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Ribavirin, Peginterferon alfa-2b (PEG-Intron), Peginterferon alfa-2a [Pegasys]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
41
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2016 · Synced Oct 9, 2026, 9:46 AM EDT
Completed Phase 2 Interventional Results available

Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease

NCT02301936
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
LDV/SOF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Lutherville, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Oct 9, 2026, 9:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Adults to Evaluate Effect of Food on Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir

NCT00909311
View directory record Official record
Conditions
HCV Infection
Interventions
ABT-450, ritonavir
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Waukegan, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 13, 2010 · Synced Oct 9, 2026, 9:46 AM EDT
Completed Phase 3 Interventional Results available

Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment

NCT00006164
View directory record Official record
Conditions
Chronic Hepatitis c, Cirrhosis, Liver, Fibrosis, Liver, Hepatic Cirrhosis
Interventions
Peginterferon alfa-2a + Ribavirin, Peginterferon alfa-2a
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
1,050 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
11
States / cities
Long Beach, California • Los Angeles, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Oct 9, 2026, 9:46 AM EDT
Completed Phase 2 Interventional Results available

Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus

NCT01628692
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
Daclatasvir, Simeprevir, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
San Francisco, California • Indianapolis, Indiana • Lutherville, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 9, 2026, 9:46 AM EDT
Terminated Phase 2 Interventional Results available

Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders

NCT01273064
View directory record Official record
Conditions
Hepatitis C
Interventions
CTS-1027, pegylated interferon, Ribavirin, Placebo
Drug
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
45
States / cities
Birmingham, Alabama • Coronado, California • La Jolla, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2012 · Synced Oct 9, 2026, 9:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects

NCT01511432
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
telaprevir formulation A, telaprevir Formulation B, telaprevir Formulation C, telaprevir Formulation D
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
2
States / cities
Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 4, 2012 · Synced Oct 9, 2026, 9:46 AM EDT
Completed No phase listed Observational

A Study to Examine Patient Characteristics, Health Care Management and Health Outcomes of Hepatitis C Virus (HCV) Patients Treated With Simeprevir

NCT02103699
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
No intervention
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
32
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Oct 9, 2026, 9:46 AM EDT
Completed Phase 1 Interventional

Fourteen Day Safety of Low-Dose Tamoxifen in Patients With Chronic Hepatitis C Who Have Failed Standard Medical Therapy

NCT00749138
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
tamoxifen
Drug
Lead sponsor
Bader, Ted, M.D.
Individual
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 9, 2010 · Synced Oct 9, 2026, 9:46 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

California MEPS Hub

NCT07433985
View directory record Official record
Conditions
HIV Prevention, Sexually Transmitted Infections (STI), Preexposure Prophylaxis (PrEP), Incarceration, Hepatitis C Virus (HCV), Substance Use Disorder (SUD)
Interventions
Mobile Enhanced Prevention Support (MEPS), Control
Behavioral · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 59 Years · Male only
Enrollment
318 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
3
States / cities
Oakland, California • Riverside, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 9, 2026, 9:46 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Comparative Autoantibody and Immunologic Cell Marker Study

NCT02422875
View directory record Official record
Conditions
Autoimmune Diseases, Lupus Erythematosus, Systemic, Communicable Diseases
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2028
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 9, 2026, 9:46 AM EDT
Completed Phase 3 Interventional

UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects

NCT01979939
View directory record Official record
Conditions
Hepatitis C
Interventions
DCV/ASV/BMS-791325
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
42
States / cities
La Jolla, California • San Diego, California • San Francisco, California + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Oct 9, 2026, 9:46 AM EDT
Recruiting Not applicable Interventional

Hepatitis C Tracker Study

NCT06870019
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
GPS tracker device
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Alhambra, California • Ventura, California
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 9, 2026, 9:46 AM EDT